Inactive agent

Abstract

To provide a deactivator for deactivating the psychological or psychoactive effects of nervous odor components.SOLUTION: A deactivator comprises cis-3-hexenol, cis-3-hexenyl acetate, and at least one component selected from the group consisting of combinations thereof. The deactivator deactivates the psychological and / or psychoactive effects of secreted components.SELECTED DRAWING: None

Description

Related Application

[0001] This invention is based on the claim of priority of Japanese Patent Application: Japanese Patent Application No. 2018-100598 (filed on May 25, 2018), and the entire contents of the application are incorporated herein by reference.

Technical Field

[0002] The present disclosure relates to an inactivator that inactivates the physiological / psychological activity (modulation) action by secreted components from the human body.

Background Art

[0003] Most of the odors caused by odor components emitted from the human skin are unpleasant odors, and are generally called "body odor". For example, "aging odor" is known as a body odor peculiar to middle-aged and elderly people (see, for example, Patent Document 1). In order to eliminate the unpleasantness caused by aging odor, the aging odor suppressing fragrance composition described in Patent Document 1 contains components having an excellent masking effect on aging odor and / or components having an excellent harmonizing effect on aging odor.

[0004] Also, generally, sulfur compounds are considered to be unpleasant odor components. Patent Document 2 discloses an inhibitor for the odor of polysulfide compounds, which contains at least one selected from the group consisting of butyl 2-methylbutyrate, α-terpinene, dipentene, cis-4-heptenal, 1,4-cineole, trimethylhexyl aldehyde, and (+)-limonene oxide as an active ingredient.

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Patent Document ②

Summary of the Invention

Problems to be Solved by the Invention

[0006] The inventors noticed that there is a distinctive odor around people who are in a state of tension (stress) where their heart rate increases due to mental stress. Therefore, the inventors investigated the cause of this odor and found that it is a body odor (hereinafter referred to as "tension odor" or "stress odor" in this disclosure) caused by substances secreted and released from people in a state of tension or mental stress.

[0007] The inventors believe that components secreted and released by people in a state of tension or mental stress (for example, substances that cause tension odor) have at least one of two effects: physiological activity and psychological activity. Therefore, it is anticipated that there will be a growing demand for inactivators that inactivate the physiological activity and / or psychological activity of components secreted by people in a state of tension and / or mental stress (hereinafter referred to as "tension odor components"). [Means for solving the problem]

[0008] According to the first perspective of this disclosure, an inactivator is provided comprising at least one component selected from the group consisting of (7) cis-3-hexenol; (11) cis-3-hexenyl acetate; and combinations thereof. The inactivator inactivates the psychological and / or psychoactive effects of secretory components. [Effects of the Invention]

[0009] The inactivating agents disclosed herein can inactivate or suppress the psychological or physiological activity caused by stress odor components. [Brief explanation of the drawing]

[0010] [Figure 1] A graph showing the results in Example 5. [Modes for carrying out the invention]

[0011] The preferred forms of each of the above viewpoints are described below.

[0012] According to the preferred form of the first viewpoint described above, the inactivators are: (1) spearmint oil; (2) lavandin oil; (3) peppermint oil; (4) l-citronellal; (5) linalool; (6) dihydromyrcenol; (8) tripral; (9) benzyl acetate; (10) rosmarin oil; (12) lavender oil; (13) (R)-3,7-dimethyl-6-octennitrile; (14) (1R,6S)-2,2,6-trimethylcyclohexanecarboxylate ethyl ester; (15) eucalyptus oil; (16) γ-undecalactone; (17) rose oil; (18) (R)-2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol; (19) (-)-isoplegol; (20) 2-(t-butyl)cyclohexyl acetate The compound further comprises at least one component selected from the group consisting of syl; <21> β-damascenone; <22> hexyl acetate; <23> l-cis-rose oxide; <24> 2-phenylethyl alcohol; <25> 3,7-dimethyl-1-octanol; <26> cedar oil; <27> geranium oil; <28> 2-acetyl-2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalene; <29> l-citronellyl acetate; <30> geraniol; <31> 1-phenylethyl acetate; <32> (3S,6E)-3,7,11-trimethyldodeca-6,10-dienal; <33> 2-(2-mercaptopropan-2-yl)-5-methylcyclohexanone; <34> terpineol; and combinations thereof.

[0013] According to the preferred form of the first viewpoint described above, the secreted component is a component secreted from within the body as a result of tension and / or mental stress.

[0014] According to the preferred form of the first viewpoint described above, the secretory component comprises at least one of allyl mercaptan and dimethyl trisulfide.

[0015] According to the preferred embodiment of the first viewpoint described above, the secretory component further contains at least one of dimethyl disulfide and methylpropyl trisulfide.

[0016] According to the preferred form of the first viewpoint described above, the secretory component further comprises 1-octen-3-one.

[0017] According to the second perspective of this disclosure, (1) spearmint oil; (2) lavandin oil; (3) peppermint oil; (4) l-citronellal; (5) linalool; (6) dihydromyrcenol; (7) cis-3-hexenol; (8) tripral; (9) benzyl acetate; (10) rosmarin oil; (11) cis-3-hexenyl acetate; (12) lavender oil; (13) (R)-3,7-dimethyl-6- Octennitrile; <14> (1R,6S)-2,2,6-trimethylcyclohexanecarboxylate ethyl ester; <15> Eucalyptus oil; <16> γ-Undecalactone; <17> Rose oil; <18> (R)-2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol; <19> (-)-Isoplegol; <20> 2-(t-butyl acetate) )Cyclohexyl; <21>β-Damascenone; <22>Hexyl acetate; <23>l-cis-rose oxide; <24>2-phenylethyl alcohol; <25>3,7-dimethyl-1-octanol; <26>Cedar oil; <27>Geranium oil; <28>2-Acetyl-2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalene; <29>l-vinegar A deodorant for tension odor is provided, comprising at least one component selected from the group consisting of citronellyl acid; <30> geraniol; <31> 1-phenylethyl acetate; <32> (3S,6E)-3,7,11-trimethyldodeca-6,10-dienal; <33> 2-(2-mercaptopropan-2-yl)-5-methylcyclohexanone; <34> terpineol; and combinations thereof.

[0018] According to the preferred embodiment of the second viewpoint described above, the stress odor deodorant contains at least one of the above components (1) to (34) and combinations thereof as a masking agent for stress odor.

[0019] According to a preferred form of the second viewpoint, the stress odor preventive agent contains at least one of the above components <1> to <22> and combinations thereof as a harmonizing agent for stress odor.

[0020] According to a preferred form of the second viewpoint, the stress odor preventive agent contains at least one of the above components <1> to <22> and combinations thereof as a masking agent and a harmonizing agent for stress odor.

[0021] According to a preferred form of the second viewpoint, stress odor is an odor emitted from the body due to a tense state and / or mental stress.

[0022] According to a preferred form of the second viewpoint, the causative substance of stress odor contains at least one of allyl mercaptan and dimethyl trisulfide.

[0023] According to a preferred form of the second viewpoint, the causative substance further contains at least one of dimethyl disulfide and methyl propyl trisulfide.

[0024] According to a preferred form of the second viewpoint, the causative substance further contains 1-octen-3-one.

[0025] Stress odor is a sulfurous odor and an odor that many people will find unpleasant. In recent years, due to the increasing interest in body odor, it is expected that the demand for deodorants that can eliminate or reduce the discomfort caused by stress odor will increase.

[0026] The odor inhibitor described in Patent Document 2 only mentions malodors from outside the human body such as drainage outlets and garbage, and has not examined malodors emitted from the human body. It is unclear whether the odor inhibitor described in Patent Document 2 can suppress stress odor.

[0027] The deodorant described herein can eliminate or reduce discomfort caused by body odor.

[0028] A deodorant according to the first embodiment of this disclosure will be described.

[0029] The deodorants disclosed herein are suitably applicable to body odor (stress odor) emitted when a person is in a state of tension and / or mental stress. Deodorants as used in this disclosure refer to a sensory action that prevents the perception of or mitigates an odor to be deodorized (hereinafter referred to as "malodor"). The deodorant action of the deodorants disclosed herein can be considered to be a masking action (masking effect) and a harmonizing action (harmonizing effect). In this disclosure, masking means preventing a malodor relatively by having a pleasant scent (fragrance, aroma) compete with the malodor. In this disclosure, harmonizing means preventing a malodor (eliminating or mitigating a malodor) by mixing a fragrance that harmonizes with the malodor with the malodor to harmonize the overall smell (for example, converting a malodor into a fragrance / aroma).

[0030] The deodorant of this disclosure comprises, as a first deodorant component, at least one of the following components: <1> Spearmint oil; <2> Lavandin oil; <3> Peppermint oil; <4> l-Citronellal; <5> Linalool; <6> Dihydromyrcenol (2,6-dimethyl-7-octen-2-ol); <7> cis-3-hexenol; <8> Tripral (dimethyl-3-cyclohexen-1-carbaldehyde); <9> Benzyl acetate; <10> Rosmarin oil (rosemary oil); <11> cis-3-hexenyl acetate; <12> Lavender oil; <1 3) (R)-3,7-dimethyl-6-octennitrile (commercially available, for example, LEVOCITRILE (registered trademark: Takasago International Corporation)); 14) (1R,6S)-2,2,6-trimethylcyclohexanecarboxylate ethyl ester (commercially available, for example, THESARON (registered trademark: Takasago International Corporation)); 15) Eucalyptus oil; 16) γ-undecalactone; 17) Rose oil; 18) (R)-2-methyl-4-(2 ,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol (commercial products include, for example, HINDINOL (registered trademark: Takasago International Corporation)); <19>(-)-isoplegol (commercial products include, for example, COOLACT (registered trademark: Takasago International Corporation) P); <20>2-(t-butyl)cyclohexyl acetate (commercial products include, for example, VERDOX (International Flavors and Fragrances) (IFF) Co.); <21> β-Damascenone (1-(2-butenoyl)-2,6,6-trimethyl-1,3-cyclohexadiene); <22> Hexyl acetate; <23> l-cis-rose oxide ((2S,4R)-tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-2H-pyran); <24> 2-phenylethyl alcohol; <25> 3,7-dimethyl-1-octanol (Commercial products include, for example, DIHYDRO CITRONELLOL (Takasago International Corporation)); <26> Cedar oil; <27> Geranium oil; <28> 2-Acetyl-2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalene (commercially available, for example, ORBITONE (registered trademark: Takasago International Corporation)); <29> l-Citronellyl acetate; <30> Geraniol; <31> 1-Phenylethyl acetate;<32> (3S,6E)-3,7,11-trimethyldodeca-6,10-dienal (commercially available, e.g., BIOMUUET (registered trademark: Takasago International Corporation)); <33> 2-(2-mercaptopropan-2-yl)-5-methylcyclohexanone (commercially available, e.g., RINGONOL (registered trademark: Takasago International Corporation) 50); <34> Terpineol; <35> Lime oil; <36> Orange peel oil; <37> Lemon oil; <38> Isoeugenol; <39> Phenylacetaldehyde; <40> α-Hexylcinnamaldehyde; <41> Cyclamate Naldehyde (3-(4-isopropylphenyl)isobutyraldehyde); <42> 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-1-one (commercially available, e.g., DYNASCONE (registered trademark: Filmenitzg)); <43> 3-(4-methoxyphenyl)-2-methylpropanal (commercially available, e.g., CANTHOXAL (IFF)); <44> 1,1,2,3,3-pentamethyl-6,7-dihydroindan-4(5H)-one (commercially available, e.g., CASHMERAN (IFF)); <45> trans-β-damascone; <46> trans-α-damascone; <47> hexyl salicylate; <48> isocyclocitral (2,4,6-trimethyl-3-cyclohexen-1-carboxyaldehyde); <49> α-amyl cinnamaldehyde; <50> methyl 2-nonate; <51> methyl anthranilate; <52> linalyl acetate; <53> octanal; <54> decanal; <55> dodecanal; <56> cis-3-hexen-1-yl salicylate; <57> allylamyl glycolate; <58> methyl(Z)-3- Hexenyl; <59> 5-methyl-3-heptanone oxime (commercially available, e.g., STEMONE (registered trademark: Dibaudan Co., Ltd.)); <60> Ethyl 2-tricyclo[5.2.1.02,6]decane-2-ylcarboxylate (commercially available, e.g., FRUITATE (registered trademark: Kao Corporation)); <61> Allyl hexanoate; <62> Allyl cyclohexanepropionate; <63> Anethole; <64> Thymol; <65> cis-jasmone; <66> 2'-acetonaphthone; <67> 4-methoxytoluene; <68> p-anisaldehyde;<69> β-ionone; <70> coumarin; <71> methyl cinnamate; <72> maltol; <73> ethyl maltol; <74> isobutylquinoline; <75> 2-isobutylquinoline; and combinations thereof.

[0031] The deodorant of this disclosure preferably contains, as a masking agent, at least one selected from the group consisting of components <1> to <37> and combinations thereof. When the deodorant of this disclosure is a masking agent, it is more preferable from the viewpoint of masking effect to contain at least one component selected from the group consisting of components <1> to <24>, <26>, <27>, <31>, and <35> to <37> and combinations thereof, and even more preferable to contain at least one component selected from the group consisting of components <1> to <6> and <35> and combinations thereof.

[0032] The deodorant of this disclosure preferably contains, as a harmonizing agent, at least one selected from the group consisting of components <1> to <22> and <35> to <37>, and combinations thereof. When the deodorant of this disclosure is a harmonizing agent, it is more preferable from the viewpoint of harmonizing effect to contain at least one component selected from the group consisting of components <1> to <19> and <35> to <37>, and combinations thereof, and even more preferable to contain at least one component selected from the group consisting of components <1> to <18>, and combinations thereof.

[0033] The deodorants of this disclosure can utilize both masking and harmonizing properties. That is, the deodorants of this disclosure can contain both a masking agent and a harmonizing agent. In particular, components <1> to <22> and <35> to <37>, as well as combinations thereof, possess both masking and harmonizing properties, and can effectively deodorize odors.

[0034] This disclosure describes how to use the deodorant and how to eliminate stress odor.

[0035] The deodorant of this disclosure can be sprayed into the air before and / or after a stress odor occurs and / or is likely to occur. The deodorant can also be applied to or sprayed onto fabric products such as clothing, curtains, and carpets before and / or after use. If the deodorant does not adversely affect the skin, it can be applied to the skin before and / or after use. For example, the deodorant can be applied to areas where stress odor components are thought to be secreted, such as the palms of the hands, armpits, feet, back, head, face, and mouth.

[0036] The deodorant disclosed herein can be used in combination with other deodorants, or with agents that remove or mitigate malodors through chemical, biological, or physical action. For example, the deodorant disclosed herein may further contain deodorizing components, odor-removing components, other deodorizing components, etc., to the extent that they do not interfere with the effect of the deodorant disclosed herein.

[0037] The deodorant disclosed herein can eliminate or alleviate the unpleasant feeling that arises when one smells stress-related odors. Furthermore, by using the deodorant disclosed herein, individuals who are or have been in a state of stress or mental stress, or who are at risk of becoming stressed or mentally stressed, can eliminate or reduce, both before and after, the anxiety that they may be emitting stress-related odors or that they may be emitting stress-related odors.

[0038] A deodorant according to a second embodiment of this disclosure will be described.

[0039] The deodorant according to the second embodiment may further contain, in addition to the deodorant according to the first embodiment, a second deodorant component that physically and chemically deodorizes (deodorizes) malodorous odors. The second deodorant component refers to a component that removes or mitigates (deodorizes) malodorous odors through chemical and / or physical action on odor-causing substances. It should be noted that even if the components listed in this disclosure remove or mitigate malodorous odors through means other than chemical and / or physical action, this does not fall outside the scope of the deodorant according to this disclosure.

[0040] The second deodorizing component includes at least one of the first deodorizing component and the second deodorizing component.

[0041] The first deodorizing component may include at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, camsnar extract, lumpuyan extract, and combinations thereof. The first deodorizing component is considered useful for deodorizing malodors, particularly those caused by allyl mercaptan, among the substances that cause stress odors.

[0042] In this disclosure, silver-supported zeolite includes, for example, zeolite in which at least a portion of the ion-exchangeable ions in the zeolite are replaced with silver ions. The silver ion content in the silver-supported zeolite can be, for example, 0.1% by mass to 15% by mass.

[0043] The second deodorizing component may include at least one selected from a second group consisting of laponite, silver-supported zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-β-cyclodextrin, sanna extract, tocopherol, dibutylhydroxytoluene, sugarcane extract, loquat leaf extract, green tea extract, and combinations thereof. The second deodorizing component is considered useful for deodorizing malodors, particularly those caused by dimethyl trisulfide, among the substances that cause stress odors.

[0044] The second deodorizing component preferably comprises (A) zinc oxide and (B) at least one selected from a third group consisting of laponite, silver-supported zeolite, dibutylhydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-β-cyclodextrin, sanna extract, green tea extract, and combinations thereof. This combination can further enhance the deodorizing effect on tension odors.

[0045] Zinc oxide can be used in the form of a fine powder. The average particle size of zinc oxide can be, for example, 5 μm or less, 3 μm or less, 2 μm or less, 1 μm or less, or 0.5 μm or less.

[0046] The main components of the odor associated with tension, as described later, are allyl mercaptan and dimethyl trisulfide. Both substances have a particularly strong effect on the sense of smell. Therefore, by eliminating the odor of allyl mercaptan and dimethyl trisulfide, the odor associated with tension can be effectively eliminated.

[0047] The second deodorizing component has a deodorizing effect against stress-related odors. Therefore, according to the deodorizer of the second embodiment, the deodorizing effect against stress-related odors can be further enhanced by combining the first deodorizing component and the second deodorizing component.

[0048] An inactivator according to a third embodiment of this disclosure will be described.

[0049] Stress odor components have at least one of the following effects on humans: psychological activity and / or physiological activity. For example, it is becoming clear that when a person perceives a stress odor, or when olfactory receptors respond to stress odor components, that person may experience mental fatigue, confusion, or arousal. Stress odor components may also have other psychological and / or mental activity effects. The inactivators of the present disclosure have the effect of inactivating such psychological and / or mental activity effects of stress odor components. That is, when a person perceives the scent of the inactivator of the present disclosure, when they smell a mixture of the scent of the inactivator and stress odor, or when olfactory receptors respond to the inactivator, that person can eliminate or suppress the mental and / or psychological disturbances described above.

[0050] In particular, it was found that when people perceive tension odors, negative emotions increase. It was also found that positive emotions tend to decrease. Examples of negative emotions include "anger / hostility," "confusion / embarrassment," "depression / downcast," "fatigue / apathy," and "tension / anxiety," based on the POMS (Profile of Mood States) test. Tension odors were found to particularly increase "confusion / embarrassment," "fatigue / apathy," and "tension / anxiety." Examples of positive emotions include "vitality / energy" and "friendliness."

[0051] The inactivator of this disclosure comprises, as the first inactivating component, at least one of the following components: <1> Spearmint oil; <2> Lavandin oil; <3> Peppermint oil; <4> l-Citronellal; <5> Linalool; <6> Dihydromyrcenol (2,6-dimethyl-7-octen-2-ol); <7> cis-3-hexenol; <8> Tripral (dimethyl-3-cyclohexen-1-carbaldehyde); <9> Benzyl acetate; <10> Rosmarin oil (rosemary oil); <11> cis-3-hexenyl acetate; <12> Lavender oil; <13> (R)-3 ,7-dimethyl-6-octennitrile (commercially available, e.g., LEVOCITRILE (registered trademark: Takasago International Corporation)); <14> (1R,6S)-2,2,6-trimethylcyclohexanecarboxylate ethyl ester (commercially available, e.g., THESARON (registered trademark: Takasago International Corporation)); <15> Eucalyptus oil; <16> γ-undecalactone; <17> Rose oil; <18> (R)-2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol (commercially available, e.g., HINDINOL (registered trademark: Takasago International Corporation)); <19> (-)-isoplegol (commercially available, e.g., COOLACT (registered trademark: Takasago International Corporation) P); <20> 2-(t-butyl)cyclohexyl acetate (commercially available, e.g., VERDOX (International Flavors and Fragrances (I) FF) Co.); <21> β-Damascenone (1-(2-butenoyl)-2,6,6-trimethyl-1,3-cyclohexadiene); <22> Hexyl acetate; <23> l-cis-rose oxide ((2S,4R)-tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-2H-pyran); <24> 2-phenylethyl alcohol; <25> 3,7-dimethyl-1-octanol (commercial products include, for example, DIHYDRO CITRONELLOL (Takasago International Corporation)); <26> Cedar oil; <27> Geranium oil; <28> 2-Acetyl-2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalene (commercially available, for example, ORBITONE (registered trademark: Takasago International Corporation)); <29> l-Citronellyl acetate; <30> Geraniol; <31> 1-Phenylethyl acetate;<32> (3S,6E)-3,7,11-trimethyldodeca-6,10-dienal (commercially available, e.g., BIOMUUET (registered trademark: Takasago International Corporation)); <33> 2-(2-mercaptopropan-2-yl)-5-methylcyclohexanone (commercially available, e.g., RINGONOL (registered trademark: Takasago International Corporation) 50); <34> Terpineol; <35> Lime oil; <36> Orange peel oil; <37> Lemon oil; <38> Isoeugenol; <39> Phenylacetaldehyde; <40> α-Hexylcinnamaldehyde; <41> Cyclamate Naldehyde (3-(4-isopropylphenyl)isobutyraldehyde); <42> 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-1-one (commercially available, e.g., DYNASCONE (registered trademark: Filmenitzg)); <43> 3-(4-methoxyphenyl)-2-methylpropanal (commercially available, e.g., CANTHOXAL (IFF)); <44> 1,1,2,3,3-pentamethyl-6,7-dihydroindan-4(5H)-one (commercially available, e.g., CASHMERAN (IFF)); <45> trans-β-damascone; <46> trans-α-damascone; <47> hexyl salicylate; <48> isocyclocitral (2,4,6-trimethyl-3-cyclohexen-1-carboxyaldehyde); <49> α-amyl cinnamaldehyde; <50> methyl 2-nonate; <51> methyl anthranilate; <52> linalyl acetate; <53> octanal; <54> decanal; <55> dodecanal; <56> cis-3-hexen-1-yl salicylate; <57> allylamyl glycolate; <58> methyl(Z)-3- Hexenyl; <59> 5-methyl-3-heptanone oxime (commercially available, e.g., STEMONE (registered trademark: Dibaudan Co., Ltd.)); <60> Ethyl 2-tricyclo[5.2.1.02,6]decane-2-ylcarboxylate (commercially available, e.g., FRUITATE (registered trademark: Kao Corporation)); <61> Allyl hexanoate; <62> Allyl cyclohexanepropionate; <63> Anethole; <64> Thymol; <65> cis-jasmone; <66> 2'-acetonaphthone; <67> 4-methoxytoluene; <68> p-anisaldehyde;<69> β-ionone; <70> coumarin; <71> methyl cinnamate; <72> maltol; <73> ethyl maltol; <74> isobutylquinoline; <75> 2-isobutylquinoline; and combinations thereof.

[0052] From the viewpoint of the inactivator and inactivating effect of the present disclosure, it is preferable to include at least one selected from the group consisting of components <1> to <37> and combinations thereof, more preferably to include at least one component selected from the group consisting of components <1> to <24>, <26>, <27>, <31>, and <35> to <37> and combinations thereof, and even more preferably to include at least one component selected from the group consisting of components <1> to <6> and <35> and combinations thereof.

[0053] The psychological and physiological activating effects of stress-induced odor components, as well as the inactivating effects of inactivating agents on stress-induced odor components, can be investigated, for example, using psychological questionnaires such as POMS (Profile of Mood States) or GACL (General Activity Checklist).

[0054] This disclosure describes a method for using the inactivator and a method for inactivating odor components.

[0055] The inactivators disclosed herein can be sprayed into the air before and / or after the occurrence of odor-causing compounds. The inactivators can also be applied to or sprayed onto fabric products such as clothing, curtains, and carpets before and / or after the occurrence of odor-causing compounds. If the inactivators do not adversely affect the skin, they can be applied to the skin before and / or after the occurrence of odor-causing compounds. For example, the deodorant can be applied to areas where odor-causing compounds are thought to be secreted, such as the palms of the hands, armpits, feet, back, head, face, and mouth.

[0056] The inactivators disclosed herein can be used in combination with other psychological and physiological inactivators, etc. For example, the inactivators disclosed herein may further contain other inactivators to the extent that they do not inhibit the effect of the inactivators disclosed herein. Examples of other inactivators include those that remove or mitigate malodors (e.g., stress odors) through chemical, biological, or physical actions (e.g., deodorizing components, odor-eliminating components, etc.).

[0057] The inactivators disclosed herein can inactivate the psychoactive and / or psychological effects of stress odor components. This makes it possible to eliminate or suppress psychological and physiological disturbances caused by stress odor components. Persons who are or have been in a state of tension or mental stress, or who are at risk of becoming tense or mentally stressed, can take measures against psychological and physiological disturbances before and / or after using the inactivators disclosed herein.

[0058] A deactivator according to a fourth embodiment of this disclosure will be described.

[0059] The inactivator according to the fourth embodiment further comprises, in addition to the inactivator according to the third embodiment, at least one of the second inactivator component and the third inactivator component.

[0060] The second inactivating component may include at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, camsnar extract, lumpuyan extract, and combinations thereof. The first inactivating component is considered useful for inactivating malodors, particularly those caused by allyl mercaptan, among the substances that cause stress odors.

[0061] The third inactivating component may include at least one selected from the second group consisting of laponite, silver-supported zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-β-cyclodextrin, sanna extract, tocopherol, dibutylhydroxytoluene, sugarcane extract, loquat leaf extract, green tea extract, and combinations thereof. The second inactivating component is considered useful for inactivating malodors, particularly those caused by dimethyl trisulfide, among the substances that cause malodors.

[0062] The third inactivating component preferably comprises (A) zinc oxide and (B) at least one selected from a third group consisting of laponite, silver-supported zeolite, dibutylhydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-β-cyclodextrin, senna extract, green tea extract, and combinations thereof. This combination can further enhance the inactivating effect on tension odor.

[0063] Zinc oxide can be used in the form of a fine powder. The average particle size of zinc oxide can be, for example, 5 μm or less, 3 μm or less, 2 μm or less, 1 μm or less, or 0.5 μm or less.

[0064] As will be discussed later, the main components of the substances causing stress-related odor are allyl mercaptan and dimethyl trisulfide. Both substances have a particularly strong effect on the sense of smell. Therefore, by deodorizing the odors of allyl mercaptan and dimethyl trisulfide, the psychological and / or physiological effects caused by stress-related odor can be effectively inactivated.

[0065] The inactivator according to the fourth embodiment can further inactivate the mental and / or psychological activating effects of the stress odor component by containing a second and / or third inactivating component having a different effect from the first inactivating component.

[0066] The method for producing the deodorant and inactivator described herein is not particularly limited. For example, the deodorant and inactivator can be produced by mixing deodorant components.

[0067] The tension odor and tension odor components referred to in this disclosure will be explained below.

[0068] Stress odor is an odor emitted from the body when a person is stressed or anxious. Stress or anxiety, in this context, can include, for example, tension or stress related to interpersonal relationships. Examples of tension or stress related to interpersonal relationships include the tension or stress experienced while giving a presentation in front of others (especially a large group), or the tension or stress experienced during an important or stressful interview. Such a state of mental stress can also be described as a condition in which the heart rate is 20 bpm (beats per minute) or more, preferably 30 bpm or more, higher than the normal resting state, provided there is no increase in heart rate due to exercise. Normal resting state refers to a state of rest without mental stress where the heart rate fluctuates little, for example, a relaxed state after sitting for a certain period of time.

[0069] Body odor is thought to be based on components present in the blood. In this disclosure, "originating from within the body (secretion / release)" means originating from (secretion / release) the skin, mucous membranes and / or oral cavity. "Body odor" as used in this disclosure also includes bad breath.

[0070] The odor component contains a compound containing the element sulfur (sulfur compound). Examples of sulfur compounds include at least one of allyl mercaptan and dimethyl trisulfide. Preferably, the odor component contains both allyl mercaptan and dimethyl trisulfide.

[0071] Allyl mercaptan may be present at a volume level of 0.1 ppb or more, 0.3 ppb or more, 0.5 ppb or more, 1 ppb or more, or 10 ppb or more. Allyl mercaptan may be present at a volume level of 1,000 ppm or less, 100 ppm or less, 10 ppm or less, 1 ppm or less, 500 ppb or less, 100 ppb or less, or 10 ppb or less.

[0072] Dimethyl trisulfide may be present in a volume-based concentration of 1 ppb or more, 2 ppb or more, 3 ppb or more, 5 ppb or more, 10 ppb or more, 20 ppb or more, 50 ppb or more, or 100 ppb or more. Dimethyl trisulfide may be present in a volume-based concentration of 10,000 ppm or less, 1,000 ppm or less, 100 ppm or less, 10 ppm or less, 1 ppm or less, 100 ppb or less, or 10 ppb or less.

[0073] In the odor component, the mass ratio of allyl mercaptan to dimethyl trisulfide can be, for example, 2 parts by mass or more, 5 parts by mass or more, 10 parts by mass or more, or 15 parts by mass or more of dimethyl trisulfide per 1 part by mass of allyl mercaptan. The mass ratio of allyl mercaptan to dimethyl trisulfide can be, for example, 50 parts by mass or less, 40 parts by mass or less, 30 parts by mass or less, or 25 parts by mass or less of dimethyl trisulfide per 1 part by mass of allyl mercaptan.

[0074] The odor component may further contain at least one compound selected from the group consisting of hydrogen sulfide, methyl mercaptan, carbon disulfide, dimethyl sulfide, dimethyl disulfide, methyl propyl trisulfide, and combinations thereof, as a sulfur compound other than allyl mercaptan and dimethyl trisulfide (hereinafter referred to as "other sulfur compounds"). The total amount of sulfur compounds may be 0.1 ppb or more, 1 ppb or more, or 10 ppb or more by volume. The total amount of sulfur compounds may be 10,000 ppm or less, or 1,000 ppm or less by volume.

[0075] The odor component may contain 1-octen-3-one as a non-sulfur compound, either additionally to or alone with respect to the sulfur compound. The concentration of 1-octen-3-one may be, for example, 0.1 ppb or more, 0.5 ppb or more, 1 ppb or more, 10 ppb or more, 100 ppb or more, or 1 ppm or more by volume. The concentration of 1-octen-3-one may be, for example, 1,000 ppm or less, 100 ppm or less, 10 ppm or less, or 1 ppm or less by volume. [Examples]

[0076] Examples of the deodorants and inactivators described herein are given below. However, the deodorants and inactivators described herein are not limited to the following examples.

[0077] [Example 1: Masking test and harmonizing test] A medium-chain fatty acid solution of the stress odor was prepared by dissolving the stress odor components shown in Table 1 in medium-chain fatty acids. Next, 10 μL of the deodorants (inactivators) shown in Tables 2 and 3 were added to 100 μL of this stress odor medium-chain fatty acid solution to prepare test solutions for each deodorant. Next, each test solution was impregnated into a 2 cm square piece of filter paper. Then, the filter paper was placed in a 500 mL disposable beaker and the beaker was sealed with aluminum foil. Thirty minutes after sealing, a hole approximately 1 cm in diameter was made in the aluminum foil. A panel of 17 experts, consisting of perfumers and evaluators, smelled through the hole and performed a sensory evaluation of the masking and harmonizing effects of each deodorant on the stress odor according to the following criteria. The average evaluation scores of the 17 experts are shown in Tables 2 and 3.

[0078] [Table 1]

[0079] [Sensory score of masking effect] 3 points: The tension odor is very well masked; Two points: The tension smell is well masked; 1 point: The sense of tension is somewhat masked; 0 points: The sense of tension is not masked.

[0080] [Sensory score of the harmonizing effect] 1 point: The tension odor and the deodorant are in harmony; 0 points: It cannot be said whether the tension odor and the deodorant are in harmony or not; -1 point: The tension odor and the deodorant do not blend well together.

[0081] The deodorants in Test Examples 1-37 achieved a masking effect score of 1.5 or higher, indicating their effectiveness in mitigating stress-related odors. In particular, deodorants with a score of 2 or higher, preferably 2.5 or higher, exhibit a high masking effect against stress-related odors.

[0082] The deodorants in Test Examples 1-22 and 35-37 achieved a harmonizing effect score of 0.5 or higher, indicating their effectiveness in reducing discomfort caused by stress odors. In particular, deodorants with a score of 0.6 or higher, preferably 0.7 or higher, exhibit a high harmonizing effect against stress odors.

[0083] Furthermore, the deodorants in Test Examples 1-22 and 35-37 possess both masking and harmonizing effects. Therefore, the deodorants in Test Examples 1-22 and 35-37 were able to significantly reduce or eliminate the discomfort caused by tension odor through both effects. In particular, deodorants with a masking effect score of 2.5 or higher and a harmonizing effect score of 0.6 or higher were effective in preventing tension odor.

[0084] [Table 2]

[0085] [Table 3]

[0086] [Example 2: Deodorization test against dimethyl trisulfide] As a second deodorizing component (second inactivating component), 0.05% by mass of a deodorant and 99.95% by mass of dipropylene glycol were mixed to prepare deodorant solutions for each deodorant. 1 mL of the deodorant solution was used, and 5 × 10⁶ of 1 part by mass of the deodorant was used. -4 Parts by mass of dimethyl trisulfide were injected into 30 mL sample tubes. Three expert panelists smelled the contents of the sample tubes and evaluated the deodorizing effect of each deodorant on dimethyl trisulfide according to the following criteria.

[0087] [Deodorizing effect against stress-related odor-causing substances] Two points: A panel of experts evaluated the deodorizer as having a high deodorizing effect; 1 point: A panel of experts rated the deodorizer's deodorizing effect as moderately high; 0 points: A panel of experts assessed that the deodorizer had no deodorizing effect.

[0088] Table 4 shows the deodorizers tested and the evaluation of their deodorizing effect by a panel of experts. The evaluations shown in Table 4 are the average scores of the expert panel, expressed according to the following criteria. The average particle size of the zinc oxide used in the following examples was approximately 0.2 μm.

[0089] A: 2 points; B: 1.5 points or more, but less than 2 points; C: 1 point or more but less than 1.5 points; D: Less than 1 point.

[0090] The deodorants in Test Examples 51-55 were found to be effective against dimethyl trisulfide, a substance that causes stress-related odor. Therefore, the deodorants in Test Examples 51-55 are considered effective in eliminating stress-related odor.

[0091] [Table 4]

[0092] [Example 3: Deodorization test against allyl mercaptan] A deodorant solution was prepared for each deodorant by mixing 0.10% by mass of a deodorant as a second deodorizing component (second inactivating component) with 99.90% by mass of dipropylene glycol. 1 mL of the deodorant solution was used, and 5 × 10⁶ of the deodorant per 1 part by mass was used. -6 Parts by mass of allyl mercaptan were injected into 30 mL sample tubes. Three expert panelists smelled the contents of the sample tubes and evaluated the deodorizing effect of each deodorant on allyl mercaptan according to the following criteria. Table 5 shows the deodorants tested and the expert panel's evaluation of the deodorizing effect of each deodorant. The evaluation criteria were the same as in Example 2.

[0093] The deodorants in Test Examples 60-68 demonstrated deodorizing effects against allyl mercaptan, a substance that causes stress-related odor. Therefore, the deodorants in Test Examples 60-68 are considered effective in eliminating stress-related odor.

[0094] [Table 5]

[0095] [Example 4: Deodorization test against allyl mercaptan] A deodorant solution was prepared for each deodorant by mixing 0.10% by mass of a deodorant as a second deodorizing component (second inactivating component) with 99.90% by mass of dipropylene glycol. The deodorant contains 50% by mass of zinc oxide as component A and 50% by mass of component B as shown in Table 3. 1 mL of the deodorant solution and 2.5 × 10⁻¹⁶ per 1 part by mass of the deodorant. -6 Parts by mass of allyl mercaptan were injected into 30 mL sample tubes. Three expert panelists smelled the contents of the sample tubes and evaluated the deodorizing effect of each deodorant on allyl mercaptan according to the following criteria. Table 6 shows the deodorants tested and the expert panel's evaluation of the deodorizing effect of each deodorant. The evaluation criteria were the same as in Example 2.

[0096] Mixing zinc oxide with other deodorizers generally resulted in a greater deodorizing effect than using the deodorizing components alone. For example, comparing test examples 60, 66, 72, 73, and 75 shown in Table 2 with test examples 76, 82, 87, 88, and 90 shown in Table 3, adding zinc oxide to the deodorizer used in Example 2 resulted in a greater deodorizing effect than using the deodorizer alone. For example, laponite, hydroxypropyl-β-dextrin, sugarcane extract, loquat leaf extract, and green tea extract had low deodorizing effects when used alone, but their deodorizing effects were enhanced when mixed with zinc oxide. In other words, it is thought that these deodorizing components and zinc oxide have a synergistic effect on deodorization. Therefore, it is thought that mixing multiple types of deodorizing components is more effective in deodorizing stress odors. In particular, deodorizers containing zinc oxide as a second deodorizing component are thought to be more effective in deodorizing stress odors.

[0097] Comparing Test Example 62 and Test Example 78, it was found that increasing the amount of zinc oxide relative to the odor-causing substance enhanced the deodorizing effect. Therefore, increasing the amount of deodorant applied to stress odors can further enhance the deodorizing effect.

[0098] [Table 6]

[0099] [Example 5: Psychological and Mental Effects Test] Subjects were exposed to a model composition of tension odor, and psychological and mental changes in the subjects due to the tension odor were examined using POMS® and GACL. The results confirmed that subjects experienced alertness, fatigue, and confusion upon smelling the tension odor.

[0100] Next, when subjects were exposed to the deodorant of this disclosure along with a model composition of tension odor, no psychological or mental changes as described above were observed. This confirms that the deodorant of this disclosure can inactivate the psychological and mental effects caused by tension odor (secretory components).

[0101] The following details a study analyzing changes in psychological state using the POMS (Registered Trademark) 2 Adult Short (Profile of Mood States Second Edition Adult Short) Japanese test sheet. In this psychological analysis, based on the answers to the questions, the psychological state related to negative mood indicators such as "anger / hostility," "confusion / embarrassment," "depression / downcast," "fatigue / apathy," and "tension / anxiety," as well as positive mood indicators such as "vitality / energy" and "friendliness," can be assessed. The test sheet has five questions for each indicator, and each subject was asked to score the mood presented in each question according to the following criteria (maximum score of 20 points for each indicator).

[0102] 0 points: I didn't feel the mood at all; 1 point: I felt somewhat like what was presented; 2 points: The presented mood was somewhat satisfactory; 3 points: I was quite impressed by the presented feeling; 4 points: There were many feelings presented that resonated with me.

[0103] First, the eight subjects were kept in a resting state for 20 minutes. After that, they were asked to answer the questions on the above-mentioned test form. This test will be referred to as "Test 1".

[0104] Next, using the lowest concentration model composition of tension odor that each subject could perceive from the tension odor model compositions shown in Table 7, each subject was asked to smell the tension odor for 5 minutes. After that, they were asked to answer the same questions as in Test 1. This test will be referred to as "Test 2".

[0105] Next, "Test 3" was conducted on a different day from Tests 1 and 2. For Test 3, the subjects who underwent Tests 1 and 2 were first placed in a resting state for 20 minutes, in the same manner as in Test 1. Then, each subject was asked to inhale a sample gas for 5 minutes, which consisted of 100 μL of the tension odor model composition used in Test 2 mixed with 10 μL of a deodorant having the composition shown in Table 8. After that, they were asked to answer the same questions as in Test 1.

[0106] The mean and standard deviation of scores for each indicator in tests 1-3 were calculated. The results are shown in Table 9. Figure 1 shows graphs of the mean and standard deviation of scores for each indicator.

[0107] Comparing the results of Test 1 and Test 2, as shown in Figure 1, it was found that perceiving the stress odor increased negative emotions, particularly tension, confusion, and fatigue. On the other hand, a tendency for positive emotions to decrease was also observed. From this, it was found that the stress odor has a psychological and mental effect that causes people's emotions to become unstable.

[0108] On the other hand, comparing tests 1 to 3, it was found that applying the deodorant of this disclosure to stress odor did not increase negative emotions caused by stress odor. Furthermore, positive emotions did not decrease. The score in test 3, in which the deodorant of this disclosure was applied, was equivalent to the score in the resting state in test 1. From this, it was found that the deodorant of this disclosure can inactivate (eliminate, reduce, and / or alleviate) the psychological and mental effects of stress odor.

[0109] Direct mass spectrometry analysis of the mixed gas of the tension odor model composition used in Test 3 and the deodorant of this disclosure detected each component of the tension odor model composition. Therefore, it is considered that the reason negative emotions caused by the tension odor did not increase in Test 3 was because the deodorant of this disclosure prevented the subjects from perceiving or recognizing the tension odor. This indicates that even when a tension odor is present, if it can be prevented by masking and / or harmonizing, the psychological and mental effects caused by the tension odor can be inactivated. In other words, the deodorant of this disclosure can be applied as an inactivator of the psychological and mental effects caused by tension odor.

[0110] [Table 7]

[0111] [Table 8]

[0112] [Table 9]

[0113] Some or all of the above embodiments may also be described as follows, but are not limited to the following descriptions. Each of these descriptions may also be combined with the claims set forth in the claims.

[0114] [Note 1] It contains at least one of the first deodorizing component and the second deodorizing component, The first deodorizing component comprises at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, camsnar extract, lumpuyan extract, and combinations thereof. The second deodorizing component comprises at least one selected from a second group consisting of laponite, silver-supported zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-β-cyclodextrin, sanna extract, tocopherol, and combinations thereof, as a stress odor deodorant.

[0115] [Note 2] It contains at least one of the first deodorizing component and the second deodorizing component, The first deodorizing component comprises at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, camsnar extract, lumpuyan extract, and combinations thereof. The second deodorizing component is, Zinc oxide and A deodorant for tension odors comprising laponite, silver-supported zeolite, dibutylhydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-β-cyclodextrin, sanna extract, green tea extract, and at least one selected from a third group consisting of combinations thereof.

[0116] [Note 3] It comprises at least one of the first inactivating component and the second inactivating component, The first inactivating component comprises at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, Camsnar extract, Lumpuyang extract, and combinations thereof. The second inactivating component comprises at least one selected from a second group consisting of laponite, silver-supported zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-β-cyclodextrin, senna extract, tocopherol, and combinations thereof. An inactivator that neutralizes the psychological or mental activating effects of secreted substances.

[0117] [Note 4] It comprises at least one of the first inactivating component and the second inactivating component, The first inactivating component is at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, Camsnar extract, Lumpuyang extract, and combinations thereof. The second inactivating component is, Zinc oxide and It comprises laponite, silver-supported zeolite, dibutylhydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl-β-cyclodextrin, senna extract, green tea extract, and at least one selected from a third group consisting of combinations thereof. An inactivator that neutralizes the psychological or mental activating effects of secreted substances.

[0118] Although the deodorants and inactivators of this disclosure are described based on the above embodiments and examples, they are not limited to the above embodiments and examples. Within the scope of the present invention and based on the fundamental technical concept of the present invention, various modifications, changes, and improvements can be made to each disclosed element (including the elements described in the claims, specification, and drawings). Furthermore, within the scope of the claims of the present invention, various combinations, substitutions, or selections of each disclosed element are possible.

[0119] Further issues, objectives, and embodiments (including modifications) of the present invention are also evident from the entire disclosure of the present invention, including the claims.

[0120] Regarding the numerical ranges described in this book, unless otherwise stated, it should be interpreted that any numerical value or range included within that range is specifically described in this book.

Claims

1. It comprises at least one component selected from the group consisting of cis-3-hexenol; cis-3-hexenyl acetate; and combinations thereof. An inactivator that deactivates the psychological and / or psychoactive effects of secretory components, including allyl mercaptan and dimethyl trisulfide, which are released and / or secreted from the body in a gaseous state as a result of tension and / or mental stress.

2. Spearmint oil; lavandin oil; peppermint oil; l-citronellal; linalool; dihydromyrcenol; tripral; benzyl acetate; rosmarine oil; lavender oil; (R)-3,7-dimethyl-6-octennitrile; (1R,6S)-2,2,6-trimethylcyclohexanecarboxylate ethyl ester; eucalyptus oil; γ-undecalactone; rose oil; (R)-2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol; (-)-isoplegol; 2-(t-butyl)cyclohexyl acetate; β-damascenone; hexyl acetate; l-cis - The inactivator according to claim 1, further comprising at least one component selected from the group consisting of rose oxide; 2-phenylethyl alcohol; 3,7-dimethyl-1-octanol; cedar oil; geranium oil; 2-acetyl-2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalene; l-citronellyl acetate; geraniol; 1-phenylethyl acetate; (3S,6E)-3,7,11-trimethyldodeca-6,10-dienal; 2-(2-mercaptopropan-2-yl)-5-methylcyclohexanone; terpineol; and combinations thereof.

3. The inactivator according to claim 2, wherein the secreted component further contains at least one of dimethyl disulfide and methylpropyl trisulfide.

4. The inactivator according to claim 3, wherein the secretory component further comprises 1-octen-3-one.

Images